HemaCare Corp. said Monday that it has terminated thepreviously announced asset purchase agreement for the sale oftwo of its specialty plasma donor centers.

Sherman Oaks, Calif.-based HemaCare had announced on April11 that its wholly owned subsidiary, MD Laboratories Inc.,would sell the two centers to AM-Rho Laboratories Inc. ofJacksonville, Fla., for $225,000.

The sale "just wasn't going as smoothly as we all wanted,"said Thomas Asher, HemaCare's chairman. "It was dragging out,and we decided to give them back their money and get on withour life."

Asher said that HemaCare had originally decided to sell theplasma centers because they were a cash drain on the company.The centers are now operating at break even and HemaCareisn't looking for another buyer, Asher added.

HemaCare stock (NASDAQ:HEMA) closed unchanged Monday at$1.94.

(c) 1997 American Health Consultants. All rights reserved.